Highlights of the important and interesting in the world of healthcare:
Nashville medical trade center key for economy. Forty-four percent of the people who took a poll by the Nashville Business Journal think their city’s medical trade center project is key for economic development so it should get state tax credits to draw tenants.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Healthcare jobs healthy now, but… The healthcare sector continues to create jobs as the economy recovers, but there are indications this may taper off, according to a report in American Medical News.
Aastrom on fast track to stem cell therapy. Aastrom Biosciences in Ann Arbor, Michigan, has gotten the Food and Drug Administration’s fast track designation for its pivotal clinical trial plan of an adult stem cell treatment to help people with severe cardiovascular disease avoid limb amputations, according to Xconomy Detroit.
Pfizer goes to India. Pfizer has turned to India’s Biocon to help it develop biosimilar insulin products to increase its global market share, paying $200 million upfront and promising another $150 million in milestone payments, according to Fierce Biotech.
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
Prescription drug plans and personalized medicine. While the market is driving increasing complexity in value-based prescription drug benefits, health reform and the Accountable Care Act will further shape prescription drug use and spending, according to the HEALTHPopuli blog.
Doctors on Pharma’s payroll. ProPublica has identified more than 17,000 healthcare providers (mostly doctors) who have accepted payments from pharmaceutical companies dating back to 2009, according to Consumer Reports’ Health blog.
